Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rituximab and IPI are prognostic indicators in post transplant lymphoproliferative disorders (PTLD)

Rituximab and IPI are prognostic indicators in post transplant lymphoproliferative disorders (PTLD). American Society of Clinical Oncology. 2003.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.